Low Grade Glioma Clinical Trial
Official title:
Ovarian Aging in Women Newly Diagnosed With Low Grade Glioma Treated With Temozolomide (Temodar®)
The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade Glioma (LGG). It is important to know if different patient factors and Temozolomide influence the rate of ovarian aging in women with LGG who have good long-term survival rates. This will allow better counseling about the effects of this particular chemotherapy agent on fertility in women.
Understanding how Temozolomide influences ovarian aging would be important information for physicians to predict the possibility of infertility (the inability to become pregnant) following recovery from Temozolomide treatment. Physicians would like to provide better individualized recommendations for cancer patients regarding timing of planned treatment and future pregnancy. We will do this by comparing data from the women being treated for Low Grade Glioma with Temozolomide to a similar group of women who have been unaffected by cancer or cancer treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Completed |
NCT04044937 -
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
|
Phase 2 | |
| Recruiting |
NCT03952598 -
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
|
N/A | |
| Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Recruiting |
NCT05964569 -
Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
|
Phase 2 | |
| Completed |
NCT02607397 -
ROCOCO - Low Grade Glioma - Planning Study
|
N/A | |
| Active, not recruiting |
NCT01358058 -
Proton Radiation Therapy for Gliomas
|
N/A | |
| Recruiting |
NCT03718767 -
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
|
Phase 2 | |
| Recruiting |
NCT02455245 -
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
|
Phase 3 | |
| Completed |
NCT02186262 -
Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
|
||
| Terminated |
NCT02023905 -
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
|
Phase 2 | |
| Recruiting |
NCT01386450 -
AZD6244 in Children With Low-Grade Gliomas
|
Phase 1/Phase 2 | |
| Completed |
NCT02286531 -
Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
|
N/A | |
| Active, not recruiting |
NCT04553757 -
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
|
||
| Not yet recruiting |
NCT06132685 -
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
|
Phase 2 | |
| Recruiting |
NCT04166409 -
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
|
Phase 3 | |
| Recruiting |
NCT02358187 -
A Vaccine Trial for Low Grade Gliomas
|
Phase 2 | |
| Recruiting |
NCT03871257 -
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
|
Phase 3 | |
| Terminated |
NCT01281982 -
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
|
||
| Active, not recruiting |
NCT01288235 -
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
|
Phase 2 |